INAB IN8bio, Inc.
Company Updates ·
IN8bio reported cash of $18.0 million at June 30, 2026 and a net loss of $4.8 million for the quarter, along with updates on its glioblastoma and gamma-delta T cell engager programs.
IN8bio reported cash of $21.9 million at March 31, 2026 and a net loss of $5.1 million for the quarter, and it described updated glioblastoma data and its INB-619 engager program.
Nasdaq notified IN8bio on June 24, 2025 that the company again meets Listing Rule 5550(a)(2). The exchange said the matter is now closed.
Holders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45.
IN8bio, Inc. describes itself as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers, called TCEs, for cancer and autoimmune diseases. The business section explains that gamma-delta T cells are a specialized population of naturally occurring immune cells that can regulate immune responses and differentiate between healthy and diseased tissue. It says these cells act as a functional bridge between innate and adaptive immunity, contributing to direct tumor-killing as well as immune cell recruitment and activation. The company states that multiple studies have demonstrated the robust tumor-killing ability of gamma-delta T cells. The text available for this profile ends early in the business overview, so individual product candidates, their development stages and any partners are not described in it.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $10.2 million | $17.0 million |
| Net income (loss) | -$19.4 million | -$30.4 million |
| Cash from operations | -$12.7 million | -$24.1 million |
| Cash and equivalents | $27.3 million | $11.4 million |
IN8bio, Inc. trades under the ticker INAB on NASDAQ.
IN8bio, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:6JH0.
The SEC Central Index Key (CIK) for IN8bio, Inc. is 1740279. Its filings are on SEC EDGAR.
9,858,383 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-06.
Our directory records IN8bio, Inc. under United States.
Our directory classifies IN8bio, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for IN8bio, Inc. is US45674E2081.
aibio.space lists IN8bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
IN8bio, Inc. describes itself as a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers, called TCEs, for cancer and autoimmune diseases. The business section explains that gamma-delta T cells are a specialized population of naturally occurring immune cells that can regulate immune responses and differentiate between healthy and diseased tissue.
IN8bio, Inc. reported a net loss of $19.4 million for the fiscal year ended Dec 31, 2025, and used $12.7 million of cash in operations, per its annual report to the SEC.
$10.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$18.1 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on IN8bio, dated Aug 6, 2026: "IN8bio reports second quarter 2026 results and glioblastoma survival data". IN8bio reported cash of $18.0 million at June 30, 2026 and a net loss of $4.8 million for the quarter, along with updates on its glioblastoma and gamma-delta T cell engager programs. Source.
Our latest financing story, dated Apr 28, 2025: "IN8bio expects about $1.9 million from reduced-price warrant exercises and exchanges". Holders agreed to exercise Series A and Series B warrants for cash at $0.1784 to $0.1844 per share by May 2, 2025. Two holders will swap warrants for pre-funded warrants, and IN8bio will cut the price of certain other Series B warrants to $0.45. Source.
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 3.03,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,5.08). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio